Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1694-1698

  Petrausch, U ^a   Samaras, P ^a   Haile, S R ^b   Veit Haibach, P ^a   Soyka, J D ^a   Knuth, A ^a   Hany, T F ^a   Mischo, A ^a   Renner, C ^a   Schaefer N G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Diffuse large B cell lymphoma; FDG PET CT; Follow up; Positive predictive value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; COST CONTROL; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE COST; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION EXPOSURE; RADIATION HAZARD; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC AGENTS; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955236253     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq015     Document Type: Article

References (15)

1. Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) 2009; 23: 610-615.
2. Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park) 2009; 23: 546-553.
3. Held G, Schubert J, Reiser M, Pfreundschuh M. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Semin Hematol 2006; 43: 221-229.
4. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17 (Suppl 4): iv31-iv32.
5. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 110-112.
6. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50 (Suppl 1): 21S-30S.
7. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
8. Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by wholebody positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-130.
9. Zinzani PL, Stefoni V, Tani M et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009; 27: 1781-1787.
10. Petrausch U, Samaras P, Veit-Haibach P et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010; 21(5): 1053-1057.
11. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
12. Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2005.
13. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110: 3507-3516.
14. Han HS, Escalon MP, Hsiao B et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20: 309-318.
15. Cheson B. The case against heavy PETing. J Clin Oncol 2009; 27: 1742-1743.